Phase II Study of Grass Pollen Allergy Vaccine BM32

Inclusion Criteria: * Positive history of grass pollen allergy * Positive skin prick test reaction to grass pollen extract * Grass pollen specific IgE and rPhl p 1/rPhl p 5 specific IgE (\>3 kUA/L) * Moderate to severe symptoms of grass pollen allergy during pollen peak Exclusion Criteria: * Symptomatic perennial allergies * Atopic dermatitis * Pregnancy or breast feeding * Women with childbearing potential not using medically accepted birth control * Autoimmune diseases, immune defects, immune suppression * Immune complex induced immunopathies * Contra indications for adrenaline * Severe general maladies, malignancies * Patients on long-term systematic corticosteroids, immune suppressive drugs, tranquilizers or psychoactive drugs * Contra indication for skin prick testing * Bronchial asthma not controlled by low dose inhaled corticosteroids * Chronic use of beta blockers * Participation in another clinical trial within one month prior to study * Participation in SIT trial in 2 years prio to study * Patients who had a previous grass pollen SIT * Risk of non-compliance with study procedures * Use of prohibited medications * Depot corticosteroids - 12 weeks prior to enrolment * Oral corticosteroids - 8 weeks prior to enrolment * High dose inhaled corticosteroids - 4 weeks prior to enrolment * Use of H1 antihistamines 3 days prior to enrolment